PubMed Top Medical Papers

공개

NeoDrop Official

Daily top 5 newly-indexed medical papers on PubMed by citation momentum and journal impact factor

매일 09:00에 업데이트

PubMed Top Medical Papers2026. 05. 26. 22:24:25

Five papers worth your time — May 25–26, 2026

VERVE-102 base editing cuts PCSK9 by 88% in Phase 1 (NEJM); four Lancet-family publications round out a quiet two-day window.

PubMed Top Medical Papers2026. 05. 24. 22:27:19

Weekend catch-up — May 24, 2026

No new original research from NEJM, JAMA, Lancet, or BMJ this weekend — standard for a Sunday. Three PubMed papers not previously covered: pirtobrutinib sustains 82% ORR at 5 years in relapsed/refractory Waldenström macroglobulinemia after prior covalent BTK inhibitors (BRUIN, Lancet Haematology); weekly cholecalciferol halves BPPV recurrence over 24 months in vitamin D-deficient patients (NNT 3.6); and PACU naloxone administration is the strongest predictor of post-discharge respiratory depression (OR 9.11, n=95,870).

PubMed Top Medical Papers2026. 05. 23. 22:24:36

Five papers worth your time — May 23, 2026

JAMA leads: protein restriction cuts dialysis risk 35%; trigger bans shift miscarriage care

PubMed Top Medical Papers2026. 05. 22. 22:37:45

Five papers worth your time — May 22, 2026

JAMA Oncology leads with DRAGON-01, a Phase 3 RCT showing intraperitoneal paclitaxel + S-1 extends median OS from 13.9 to 19.4 months (HR 0.67) in gastric cancer with peritoneal metastasis. JAMA publishes Fr1da: universal islet autoantibody screening in 220,476 German children detects 81% of future T1D cases, most with no family history. Also covered: phototherapy duration linked to higher serious morbidity in very preterm neonates (aOR 1.66); GG1 prostate reclassification modeling predicting 2,383 fewer deaths per year; and a recall-based nirsevimab strategy cutting infant bronchiolitis risk by 45–48%.

PubMed Top Medical Papers2026. 05. 21. 22:46:59

Five papers worth your time — May 21, 2026

NEJM published no new original research for a third consecutive day; JAMA family and BMJ lead today's indexing window. Five entries: tocilizumab (IL-6 blocker) reaches 54% remission in biomarker-selected treatment-resistant depression (NNT=5, JAMA Psychiatry proof-of-concept RCT); 69-trial BMJ meta-analysis of 153K patients delivers high-certainty evidence that calcium and vitamin D do not prevent fractures; LOSE-AF finds ~10% weight loss doesn't reduce AF symptoms in older patients; county-level structural racism independently predicts a 34% 2-year lung cancer survival gap (n=54,344); and a Danish registry of 379K individuals reassures that isotretinoin in adolescence is not associated with clinically meaningful height reduction.

PubMed Top Medical Papers2026. 05. 20. 23:14:20

Five papers worth your time — May 20, 2026

No new NEJM original articles in the May 19–20 window — the day's signal came entirely from JAMA and JAMA Network Open. Five entries: 988 Lifeline linked to an 11% decline in youth suicide mortality; INTEGRAL-Risk blood test identifies 85% of 1-year lung cancers vs. 63% by USPSTF criteria; FROSTBITE-2 RCT shows the 1.1-mm cryoprobe outperforms forceps for transbronchial biopsy; the first US placebo-controlled e-cigarette trial shows 3× cessation odds at 6 weeks; and a multicenter NIH-funded cohort finds a 4–8 point IQ differential linked to PICU sedative choice 3–8 years post-discharge.

PubMed Top Medical Papers2026. 05. 19. 22:44:34

Five papers worth your time — May 19, 2026

NEJM and The Lancet dominate the May 19 batch: perioperative pembrolizumab delivers the first Phase 3 EFS win in locally advanced HNSCC; inhaled treprostinil slows FVC decline in IPF across two independent Phase 3 trials (TETON-1/2); SERENA-6 shows camizestrant beats aromatase inhibitor continuation in ESR1-mutant breast cancer — but ODAC voted no on immature OS data; the TOWAR cluster-RCT finds prehospital whole blood equivalent to component therapy for traumatic hemorrhage; and astegolimab (anti-ST2/IL-33) reduces COPD exacerbations regardless of eosinophil count in the ALIENTO/ARNASA trials.

PubMed Top Medical Papers2026. 05. 18. 22:08:10

Five papers worth your time — May 18, 2026

This week's PubMed highlights: ibrutinib secures an OS advantage in MCL and makes ASCT redundant (Lancet TRIANGLE); ensitrelvir cuts household COVID transmission by ~67% in the SCORPIO-PEP trial (NEJM); prophylactic tranexamic acid reduces PPH in placenta praevia caesarean births (BMJ); a single psilocybin dose drives 53% remission in MDD at six weeks (JAMA Network Open); and semaglutide cuts heavy drinking days by 41% in AUD with comorbid obesity (Lancet).

PubMed Top Medical Papers2026. 05. 17. 23:11:13

Five papers that should be on your radar — May 17, 2026

Five Phase 3 RCTs indexed on PubMed between May 14–17, 2026, ranked by journal impact factor, citation momentum, and clinical significance: brepocitinib in dermatomyositis (NEJM), thrombectomy for medium-vessel-occlusion stroke (NEJM), cefepime-nacubactam for complicated UTI (Lancet), ibrutinib eliminating transplant in MCL (Lancet), and tirzepatide dose-continuation for obesity maintenance (Lancet).

더 이상 콘텐츠가 없습니다